BAT is a monoclonal antibody (mAb) produced against membranes of a human Burkitt lymphoma cell line (Daudi) that was selected for its ability to stimulate lymphocyte proliferation. BAT manifests anti-tumor properties in mice bearing a variety of murine tumors. BAT also induced regression of human tumors inoculated into SCID mice that had been engrafted with human lymphocytes. The anti-tumor activity of BAT was related to its immune stimulatory properties. Previous data indicated that T lymphocytes and NK cells mediate in vivo the anti-tumor activity. In order to define the primary target cell for BAT stimulatory activity, the in vitro stimulatory effect of BAT on purified lymphocyte subpopulations was investigated. Human CD4 ⍣ , CD8 ⍣ T cells and CD56 ⍣ NK cells were purified and their in vitro response to BAT was investigated. Results indicate that BAT selectively stimulated CD4 ⍣ cells as assessed by proliferation and secretion of IFN-γ. FACS analysis has also revealed a selective increase in BAT antigen on CD4 ⍣ T cells that were cultured with BAT antibody. The effector cells that mediate BAT-induced tumor eradication may, however, be distinct from those that serve as the primary cellular target of the antibody. Cytokines such as IFN-γ that are produced by CD4 ⍣ cells may be involved in activation of additional cell types that may be involved in tumor destruction.
Introduction
We have previously described BAT mAb that we have precells. Spleen cells were fused with NS-O myeloma cells. BAT pared against membranes of Daudi cells, a Burkitt lymphoma was selected by its ability to bind Daudi cells and to induce cell line, which binds and stimulates human T lymphocytes proliferation of human peripheral blood mononuclear cells to proliferate and elicit cytolytic activity (1) . BAT also stimulates (PBMC). Cells were grown in RPMI 1640 medium supplemurine splenocytes and induced regression of a variety of mented with FCS (10%), sodium pyruvate, glutamine and tumors in mice. Tumor regression was related to the immuneantibodies, and incubated at 37°C in a humidified atmosphere stimulatory properties of this antibody. This conclusion was containing 5% CO 2 . BAT was purified on a Protein Gsupported by adoptive transfer experiments in which splenoSepharose column according to the manufacturer's instruccytes from mice treated by BAT induced regression of tumors tions (Pharmacia, St Albans, UK). Phycoerythrin (PE)-conjugin mice (2). BAT also induced tumor regression of human ated anti-CD4 and anti-CD8 mouse anti-human mAb were melanoma xenografts in SCID mice that were engrafted with used for flow cytometry and were purchased from PharMingen human lymphocytes (3). We have previously reported that (San Diego, CA). both NK and T cells mediate the anti-tumor activity of BAT (3). In order to define the primary target cell for BAT stimulatory Cells separation and purification activity, the in vitro stimulatory effects of BAT on purified Human PBMC were obtained from blood of healthy donors CD4 ϩ , CD8 ϩ and CD56 ϩ lymphocyte subpopulations was by Ficoll-Hypaque density centrifugation. Cells were washed investigated.
and suspended in RPMI 1640 containing 5% human type AB serum (Sigma, Rehovot, Israel).
Methods
Selection of CD4 ϩ , CD8 ϩ and CD56 ϩ lymphocyte subpopulmAb ations was done using MACS magnetic microbeads (Milteny Biotech, Bergisch, Gladbach, Germany). According to the BAT was generated and purified as described (1) . In brief, BALB/c mice were immunized with membranes from Daudi manufacturer's instructions PBMC (10 8 cells) were suspended . FACS analysis histogram of CD4 ϩ , CD8 ϩ and CD56 ϩ purified lymphocyte populations as determined by staining with the related antibody labeled with PE. Anti-mouse-PE was used as isotype control. Lymphocytes were purified using anti-CD4, anti-CD8 or anti-CD56 coated magnetic beads.
medium containing 5% human AB serum. PBL and isolated lymphocyte subpopulations were incubated with BAT (0.1 µg/ ml) for 5 days in vitro.
Proliferation assays
Aliquots (200 µl) of 2ϫ10 6 cells/ml from activated PBL or activated purified T cell subpopulations were incubated in 96-well flat-bottom plates and 3 [H]thymidine (1 µCi/well) was added 20 h before harvesting. Cultures were harvested into glass filters and radioactivity was counted using a liquid β-scintillation counter. 
Flow cytometry analysis
CD56 ϩ lymphocyte subpopulations from normal blood donors (n ϭ 12). Cells were cultured for 5 days in the presence and absence of Human PBL or purified CD4 ϩ and CD8 ϩ cells before or after BAT mAb (0.1 µg/ml). The increase in PBL and CD4 ϩ cultured with BAT activation were washed twice with PBS containing 0.5%
BAT was significant (P ϭ 0.022 and P ϭ 0.008).
BSA and 0.05% Na-azide. Samples containing 0.5ϫ10 6 cells were used. Cells were incubated with a saturated amount of BAT for 45 min at 4°C followed by anti-mouse-FITC for 30 min (Jackson ImmunoResearch, West Grove, PA). After in 800 µl PBS supplemented with 0.5% BSA and 2 mM EDTA.
washing the cells, PE-conjugated antibodies anti-CD4 or antiSufficient mouse anti-human CD4-, CD8-or CD56-coated CD8 (PharMingen, San Diego, CA) were added for 30 min magnetic beads were added to the cell suspension for 15 and incubated at 4°C. min at 4°C. After washing, cells were transferred to MACS LS ϩ A FACScan (Becton Dickinson, Esembodegem, Belgium) separation columns for rapid positive selection of lymphocyte analyzed cell samples by CellQuest program. Side scatter subpopulations. Separated subpopulations were analyzed by and forward scatter of dot-plots determined the gate of cells. flow cytometry.
Calibration of the cytometer was done by FITC-and PE-T cell purification from PBMC was done by nylon wool conjugated CaliBRITE beads. Isotype controls for CD4 and columns (Uni-Sorb; Novamed, Jerusalem, Israel). Lympho-CD8 antibodies was PE-IgG1 (PharMingen). cytes (8ϫ10 7 ) were suspended in 2 ml of RPMI 1640 medium with 5% FCS. The suspension was injected slowly into the Cytokine profile nylon wool column that was then incubated at 37°C. After 1 h, the nylon wool column was washed 2 times with 10 ml
The supernatants of human PBL or purified CD4 ϩ , CD8 ϩ or CD56 ϩ lymphocytes cultured with or without BAT for 5 days of medium, and the non-adherent T cells were collected and counted.
in vitro was tested for release of human IFN-γ, tumor necrosis factor-α, IL-2, IL-6 and IL-4. Quantitative determination of Activation of lymphocytes by BAT the cytokines concentration was evaluated by an ELISA procedure using Predicta kits (Genzyme, Cambridge, MA) Human peripheral blood lymphocytes (PBL) or purified CD4 ϩ , CD8 ϩ or CD56 ϩ cells (2ϫ10 6 /ml) were incubated in culture according to the manufacturer's instructions. CD4 ϩ , CD8 ϩ and CD56 ϩ cells. Figure 1 demonstrates a FACS analysis histogram of the three purified subpopulations. Each purified population was incubated with its specific PE-labeled antibody. Non-specific labeling was determined by staining the cells with anti-mouse-PE. Incubation of PBL with BAT (0.1 µg/ml) for 5 days induced a low but significant (P ϭ 0.0227) increase in proliferation. Purified lymphocyte subpopulations were cultured at similar conditions with BAT. BAT selectively stimulated a significant increase in thymidine uptake in CD4 ϩ cells (P ϭ 0.0089) while neither CD8 ϩ nor CD56 ϩ cells responded (Fig. 2) . of PBL cultured with BAT for 5 days. As seen in four independent experiments (Fig. 3) , IFN-γ levels were increased in BATtreated cells. IL-2, IL-4 and IL-6 levels were not increased BAT-binding antigen on CD4 ϩ and CD8 ϩ cells in most cases under these experimental conditions. TNF-α Purified CD4 ϩ and CD8 ϩ cells (4ϫ10 6 cells) from normal PBL secretion was marginally increased in three out of the four were mixed with 50 µl of lysis buffer (10 mM Tris-HCl buffer, experiments. The amount of IFN-γ in supernatants of purified pH 7.6 with 5 mM EDTA, 0.14 M NaCl, 0.1 mM PMSF, 10 mM CD4 ϩ , CD8 ϩ and CD56 ϩ cells incubated with BAT was NaF and 0.5% NP-40) and incubated for 30 min at 0°C. measured. The results depicted in Fig. 4 demonstrate a The mixtures were centrifuged and the supernatants were significant increase (P ϭ 0.0523) in IFN-γ secretion in cultures collected. Samples of CD4 ϩ and CD8 ϩ cell lysates contained of purified CD4 ϩ cells contrary to cultures of purified CD8 ϩ 50 µg/lane. Daudi cell lysate was used at 10 µg/lane. Proteins or CD56 ϩ cells that were treated with BAT. BAT induced a were separated by SDS-PAGE (10%) and then transferred significant increase in IFN-γ secretion in PBL (P ϭ 0.0441). to nitrocellulose membranes. Detection of the BAT-binding protein was done by incubation with BAT mAb overnight at BAT antigen on CD4 ϩ and CD8 ϩ T lymphocytes: up-regulation 4°C followed by incubation for 45 min with peroxidaseby BAT in CD4 ϩ T cells conjugated anti-mouse IgG (Sigma, Munchen, Germany) and
Cytokine profile
The binding of BAT to normal CD4 ϩ and CD8 ϩ T lymphocytes by chemiluminescent substrate (Pierce, Rockford, IL).
was determined in 10 different normal volunteers. Percent of BAT binding to either CD4 ϩ or CD8 ϩ cells was determined using FACS analysis by double staining with BAT-FITC and Results either anti-CD4-PE or anti-CD8-PE antibodies. Total numbers BAT-induced proliferation of CD4 ϩ T cells of CD4 ϩ or CD8 ϩ cells were also determined. As seen in Fig. 5 , all CD8 ϩ cells bind BAT antibody (95 Ϯ 5%), whereas We have previously reported the ability of BAT to induce proliferation of human PBL. In order to identify the responding the percent of CD4 ϩ cells that bind BAT varies among the different individuals (68 Ϯ 30%). The expression of BATlymphocyte subpopulations, we used magnetic beads purified increase in percent of BAT-binding cells (Fig. 7) . Moreover, the intensity of BAT receptors, as determined by mean fluorescence, was also increased on purified CD4 ϩ cell populations that were cultured with BAT (from a mean fluorescence of 83 to 160). In contrast, no change in percent of BAT-binding sites and intensity was noted in CD8 ϩ cells cultured with BAT.
BAT activation does not increase IL-2 receptors
In order to elucidate whether BAT-induced lymphocyte proliferation is also manifested by an increase in the percentage of IL-2 receptors on T cells, we cultured purified T cells with BAT or anti-CD3. Incubation of T cells with anti-CD3 for 3 days induced proliferation and an increase in IL-2 receptors. In contrast, incubation of T cells with BAT for 5 days induced cell proliferation without an increase in IL-2 receptors (Table 1) .
Discussion
T cell activation has now been shown to require at least two signals. The first is antigen specific, is delivered through the for cytokine production and proliferation, and is mediated through ligand interaction on the surface of the T cell. Several such co-stimulatory molecules were described to induce immune activation of lymphocytes and subsequent increase binding protein in CD4 ϩ and CD8 ϩ cells was also determined at the molecular level using Western blot analysis. Data anti-tumor activity (4). The mAb BAT was produced against a 48 kDa monomeric protein on the membranes of a Burkitt indicated (Fig. 6 ) that both T cell subpopulations contain the BAT antigen and that the apparent mol. wt of the BAT antigen lymphoma B cell line. BAT induces stimulation of T cells accompanied by a strong anti-tumor activity. A single i.v. in the T lymphocytes is similar to that detected on Daudi cells which were used to raise the BAT mAb .
administration of BAT induced regression of a variety of tumors in mice. The anti-tumor activity of BAT was related to its The effect of BAT on the expression of BAT-binding sites in CD4 ϩ and CD8 ϩ cells was investigated. Incubation of PBL immune stimulatory properties as was also manifested by adoptive transfer of lymphocytes from BAT-treated mice. We or purified CD4 ϩ cells with BAT (0.1 µg/ml) resulted in an indicate that BAT-binding protein is expressed in both CD4 ϩ study we performed experiments to define the primary cellular and CD8 ϩ cells. However, only CD4 ϩ cells are responsive to target for BAT in human PBL. The in vitro stimulatory effect of the antibody. This finding indicates that legation of the cell BAT on selected human lymphocyte subpopulations was surface BAT-binding protein is not by itself sufficient to induce determined. Our findings indicated that BAT selectively stimuactivation. It is pertinent to note that T and B cells bind lated CD4 ϩ T cells. The significance of this finding for the equally concanavalin A, whereas the lectin induces selective anti-tumor effect of BAT is supported by recent evidence activation only of the T cells. Of interest are the findings that indicating that CD4 ϩ T cells are equally critical components BAT induces increase in BAT antigen receptors but failed to of the anti-tumor immune response (5). It was also reported increase IL-2 receptors. In contrast to anti-CD3, BAT stimulathat secondary anti-CD3/anti-CD28 activation expanded tion seems to be IL-2 independent (Table 1) . Additional tumor-reactive CD4 ϩ T cell response to human cancers. Cytokine release assays demonstrated that positively selected differences between BAT-and anti-CD3-induced anti-tumor to B lymphoblastoid cells; molecular mass and distribution of activity were recently described (9 
